Inclusion Criteria:

- Women with histological diagnosis of invasive breast cancer requiring neoadjuvant
chemotherapy

- T2 tumour or above

- WHO Performance status of 0,1 or 2

- Must consent to or have undergone a core biopsy for diagnosis of breast cancer AND
consent to undergo an additional core biopsy prior to the second cycle of
chemotherapy (Day 5 +/- Day 21)

- Written informed consent

Exclusion Criteria:

- Previous chemotherapy or radiotherapy to treated breast

- Evidence of metastatic disease or recurrent breast cancer or previous malignancy
(some exceptions)

- Calculated creatinine clearance < 40mls/min

- Prior treatment with bisphosphonates in last year or known contraindications to
bisphosphonate therapy

- Concurrent tamoxifen or aromatase inhibitor medication

- Pregnant or lactating women

- Cardiac dysfunction that precludes use of anthracycline chemotherapy

- Unwilling to have extra interim biopsy